Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medifast (MED) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $23.0 million.

  • Medifast's Cost of Revenue fell 2542.88% to $23.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $110.6 million, marking a year-over-year decrease of 2992.9%. This contributed to the annual value of $110.6 million for FY2025, which is 2992.84% down from last year.
  • According to the latest figures from Q4 2025, Medifast's Cost of Revenue is $23.0 million, which was down 2542.88% from $27.2 million recorded in Q3 2025.
  • Medifast's 5-year Cost of Revenue high stood at $131.7 million for Q2 2022, and its period low was $23.0 million during Q4 2025.
  • Moreover, its 5-year median value for Cost of Revenue was $72.0 million (2023), whereas its average is $71.1 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 11314.18% in 2021, then plummeted by 5375.22% in 2024.
  • Medifast's Cost of Revenue (Quarter) stood at $99.5 million in 2021, then rose by 4.12% to $103.6 million in 2022, then tumbled by 52.1% to $49.6 million in 2023, then plummeted by 37.99% to $30.8 million in 2024, then decreased by 25.43% to $23.0 million in 2025.
  • Its Cost of Revenue was $23.0 million in Q4 2025, compared to $27.2 million in Q3 2025 and $28.9 million in Q2 2025.